| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5965584 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166042 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166043 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6172090 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US9101660 | TAKEDA PHARMS USA | Solid preparation |
Jan, 2027
(2 years from now) | |
| US9320714 | TAKEDA PHARMS USA | Tablet |
Feb, 2029
(4 years from now) | |
Actoplus Met is owned by Takeda Pharms Usa.
Actoplus Met contains Metformin Hydrochloride; Pioglitazone Hydrochloride.
Actoplus Met has a total of 6 drug patents out of which 4 drug patents have expired.
Expired drug patents of Actoplus Met are:
- US5965584
- US6166042
- US6166043
- US6172090
Actoplus Met was authorised for market use on 29 August, 2005.
Actoplus Met is available in tablet;oral dosage forms.
Actoplus Met can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione (tzd) and metformin or who have inadequate glycemic control on a tzd or metformin alone, adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a pioglitazone and metformin.
The generics of Actoplus Met are possible to be released after 03 February, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-116) | May 17, 2015 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 August, 2005
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione (tzd) and metformin or who have inadequate glycemic...
Dosage: TABLET;ORAL
ACTOPLUS MET family patents
